RxDoctor Payments Data

Julius Elmore, MD

Cardiovascular Disease · Macon, GANPI 1457523367

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Boston Scientific at 38.3% of the total. 2025 is the largest year on record at $24,718, 3.2 times the $7,704 reported in 2019. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,918in general payments, 2019–2025

Across 479 payments — averaging $114.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • Medtronic$20K
  • Philips North America LLC$4K
  • Edwards Lifesciences$3K
  • Angiodynamics, Inc.$2K
  • Abbott$1K
  • plus $4K from 28 others
$45,000in research payments, 2019–2025

Across 1 payment — averaging $45,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$45K

What the payments were for

  • Speaking & faculty fees$28,23151%
  • Travel & lodging$10,79220%
  • Food & beverage$15,83729%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,918 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$763,178
Medicare patients
1,211
Services billed
5,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan252$312,452
EliquisApixaban310$293,754
XareltoRivaroxaban78$76,007
FarxigaDapagliflozin Propanediol53$57,777
BrilintaTicagrelor37$33,752
Repatha SureclickEvolocumab32$31,291
NexlizetBempedoic Acid/Ezetimibe38$22,747
Metoprolol Succinate766$11,715
Ranolazine ErRanolazine77$8,046
Atorvastatin Calcium590$5,377
Midodrine Hcl77$4,765
Losartan Potassium534$4,465
EdarbyclorAzilsartan Med/Chlorthalidone14$3,442
ClopidogrelClopidogrel Bisulfate309$3,327
Pyridostigmine Bromide104$3,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$443$312,452252 claims
PfizerEliquis$332$293,754310 claims
AstraZenecaFarxiga, Brilinta$182$91,52990 claims
Johnson & JohnsonXarelto$578$76,00778 claims
Esperion Therapeutics, Inc.Nexlizet$56$22,74738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →